Have a personal or library account? Click to login
Predictors for Pulmonary Tuberculosis Outcome and Adverse Events in an Italian Referral Hospital: A Nine-Year Retrospective Study (2013–2021) Cover

Predictors for Pulmonary Tuberculosis Outcome and Adverse Events in an Italian Referral Hospital: A Nine-Year Retrospective Study (2013–2021)

Open Access
|Apr 2022

References

  1. 1 World Health Organization (WHO). Global Tuberculosis Report 2021. Geneva: WHO; 2021. https://www.who.int/publications/i/item/9789240037021
  2. 2 Chakaya J, Khan M, Ntoumi F, et al. Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts. Int J Infect Dis. 2021 Mar 11; S1201–9712(21); 001934. DOI: 10.1016/j.ijid.2021.02.107
  3. 3 Togun T, Kampmann B, Stoker NG, Lipman M. Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes. Ann Clin Microbiol Antimicrob. 2020 May 23; 19(1): 21. DOI: 10.1186/s12941-020-00363-1
  4. 4 Di Gennaro F, Gualano G, Timelli L, et al. Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital. Antibiotics (Basel). 2021 Mar 8; 10(3): 272. DOI: 10.3390/antibiotics10030272
  5. 5 Pontarelli A, Marchese V, Scolari C, et al. Screening for active and latent tuberculosis among asylum seekers in Italy: A retrospective cohort analysis. Travel Med Infect Dis. 2019 Jan–Feb; 27: 3945. DOI: 10.1016/j.tmaid.2018.10.015
  6. 6 Villa S, Codecasa LR, Faccini M, et al. Tuberculosis among asylum seekers in Milan, Italy: epidemiological analysis and evaluation of interventions. Eur Respir J. 2019 Oct 31; 54(4): 1900896. DOI: 10.1183/13993003.00896-2019
  7. 7 Boudville DA, Joshi R, Rijkers GT. Migration and tuberculosis in Europe. J Clin Tuberc Other Mycobact Dis. 2020 Jan 7; 18: 100143. DOI: 10.1016/j.jctube.2020.100143
  8. 8 World Health Organization (WHO). Consolidated guidelines on tuberculosis. Geneva: WHO; 7 July 2021. https://www.who.int/publications/i/item/9789240029415
  9. 9 Palmieri F. Per il Gruppo di Lavoro Tubercolosi-INMI “L. Spallanzani” Percorso Diagnostico Terapeutico Assistenziale Sulla Gestione del Paziente con Infezione/Malattia Tubercolare. Revisione N. 8/Gennaio 2020. Accessed 30 November 2021. http://www.inmi.it/servizio/protocolli_e_linee_guida.
  10. 10 European Centre for Disease Prevention and Control & World Health Organization. Regional Office for Europe. (2020). Tuberculosis surveillance and monitoring in Europe 2020: 2018 data. World Health Organization. Regional Office for Europe. https://apps.who.int/iris/handle/10665/331530.
  11. 11 Kraef C, Bentzon A, Panteleev A, et al. Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality-a multicentre prospective cohort study. BMC Infect Dis. 2021 Oct 6; 21(1): 1038. DOI: 10.1186/s12879-021-06745-w
  12. 12 Li J, Chung PH, Leung CLK, Nishikiori N, Chan EYY, Yeoh EK. The strategic framework of tuberculosis control and prevention in the elderly: a scoping review towards End TB targets. Infect Dis Poverty. 2017 Jun 1; 6(1): 70. DOI: 10.1186/s40249-017-0284-4
  13. 13 Di Gennaro F, Vittozzi P, Gualano G, et al. Active Pulmonary Tuberculosis in Elderly Patients: A 2016–2019 Retrospective Analysis from an Italian Referral Hospital. Antibiotics (Basel). 2020 Aug 7; 9(8): 489. DOI: 10.3390/antibiotics9080489
  14. 14 Kristensen KL, Ravn P, Petersen JH, et al. Long-term risk of tuberculosis among migrants according to migrant status: a cohort study. Int J Epidemiol. 2020 Jun 1; 49(3): 776785. DOI: 10.1093/ije/dyaa063
  15. 15 Yen YF, Feng JY, Pan SW, Chuang PH, Su VY, Su WJ. Determinants of mortality in elderly patients with tuberculosis: a population-based follow-up study. Epidemiol Infect. 2017 May; 145(7): 13741381. DOI: 10.1017/S0950268817000152
  16. 16 Piergallini TJ, Turner J. Tuberculosis in the elderly: Why inflammation matters. Exp Gerontol. 2018 May; 105: 3239. DOI: 10.1016/j.exger.2017.12.021
  17. 17 Ingrosso L, Vescio F, Giuliani M, et al. Risk factors for tuberculosis in foreign-born people (FBP) in Italy: a systematic review and meta-analysis. PLoS One. 2014 Apr 14; 9(4): e94728. PMID: 24733156; PMCID: PMC3986251. DOI: 10.1371/journal.pone.0094728
  18. 18 Chemtob D, Ogum E. Tuberculosis treatment outcomes of non-citizen migrants: Israel compared to other high-income countries. Isr J Health Policy Res. 2020 Aug 3; 9(1): 29. PMID: 32741367; PMCID: PMC7397670. DOI: 10.1186/s13584-020-00386-1
  19. 19 Di Gennaro F, Pizzol D, Cebola B, et al. Social determinants of therapy failure and multi drug resistance among people with tuberculosis: A review. Tuberculosis (Edinb). 2017 Mar; 103: 4451. DOI: 10.1016/j.tube.2017.01.002
  20. 20 Hargreaves S, Lönnroth K, Nellums LB, et al. Multidrug-resistant tuberculosis and migration to Europe. Clin Microbiol Infect. 2017 Mar; 23(3): 141146. DOI: 10.1016/j.cmi.2016.09.009
  21. 21 Odone A, Riccò M, Morandi M, Borrini BM, Pasquarella C, Signorelli C. Epidemiology of tuberculosis in a low-incidence Italian region with high immigration rates: differences between not Italy-born and Italy-born TB cases. BMC Public Health. 2011 May 23; 11: 376. DOI: 10.1186/1471-2458-11-376
  22. 22 Di Gennaro F, Lattanzio R, Falanga C, et al. Low-Wage Agricultural Migrant Workers in Apulian Ghettos, Italy: General Health Conditions Assessment and HIV Screening. Trop Med Infect Dis. 2021 Oct 15; 6(4): 184. DOI: 10.3390/tropicalmed6040184
  23. 23 Merid MW, Gezie LD, Kassa GM, Muluneh AG, Akalu TY, Yenit MK. Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara regional state public hospitals; Ethiopia: A retrospective cohort study. BMC Infect. Dis. 2019; 19: 286. DOI: 10.1186/s12879-019-3919-1
  24. 24 Lan Z, Ahmad N, Baghaei P, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020 Apr; 8(4): 383394. DOI: 10.1016/S2213-2600(20)30047-3
  25. 25 Noor S, Ismail M, Khan F. Drug safety in hospitalized patients with tuberculosis: Drug interactions and adverse drug effects. Clin Respir J. 2021 Jan; 15(1): 97108. DOI: 10.1111/crj.13276
  26. 26 Borisov S, Danila E, Maryandyshev A, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J. 2019 Dec 19; 54(6): 1901522. DOI: 10.1183/13993003.01522-2019
  27. 27 Holden IK, Andersen PH, Wejse C, Lillebaek T, Johansen IS. Review of tuberculosis treatment outcome reporting system in Denmark, a retrospective study cohort study from 2009 through 2014. BMC Health Serv Res. 2020 Feb 3; 20(1): 83. PMID: 32013962; PMCID: PMC6998178. DOI: 10.1186/s12913-020-4927-y
  28. 28 Peri AM, Bernasconi DP, Galizzi N, et al. Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: a cross-sectional observational study. BMC Infect Dis. 2018 Dec 20; 18(1): 690. DOI: 10.1186/s12879-018-3609-4
  29. 29 Pezzotti P, Pozzato S, Ferroni E, et al. Delay in diagnosis of pulmonary tuberculosis: A survey in the Lazio region, Italy Epidemiology Biostatistics and Public Health. 2015; 1–10: 12.
  30. 30 Koo HK, Min J, Kim HW, et al. Prediction of treatment failure and compliance in patients with tuberculosis. BMC Infect Dis. 2020 Aug 24; 20(1): 622. DOI: 10.1186/s12879-020-05350-7
  31. 31 Riccardi N, Pontarelli A, Alagna R, et al. Epidemiology and treatment outcome of MDR and pre-XDR TB in international migrants at two reference centers in the North of Italy: a cross-sectional study coordinated by Stop TB Italia Onlus. Public Health. 2020 Mar; 180: 1721. DOI: 10.1016/j.puhe.2019.10.022
  32. 32 Aslam MV, Owusu-Edusei K, Marks SM, et al. Number and cost of hospitalizations with principal and secondary diagnoses of tuberculosis, United States. Int J Tuberc Lung Dis. 2018; 22(12): 14951504. DOI: 10.5588/ijtld.18.0260
  33. 33 Nishikiori N, Van Weezenbeek C. Target prioritization and strategy selection for active case-finding of pulmonary tuberculosis: a tool to support country-level project planning. BMC Public Health. 2013; 13: 97. DOI: 10.1186/1471-2458-13-97
  34. 34 World Health Organization (WHO). Implementing the end TB Strategy. Geneva 2015. https://www.who.int/publications/i/item/implementing-the-end-tb-strategy.
  35. 35 Saunders MJ, Evans CA. COVID-19, tuberculosis and poverty: preventing a perfect storm. Eur Respir J. 2020 Jul 9; 56(1): 2001348. DOI: 10.1183/13993003.01348-2020
  36. 36 Di Gennaro F, Marotta C, Antunes M, Pizzol D. Diabetes in active tuberculosis in low-income countries: to test or to take care? Lancet Glob Health. 2019 Jun; 7(6): e707. DOI: 10.1016/S2214-109X(19)30173-1
DOI: https://doi.org/10.5334/aogh.3677 | Journal eISSN: 2214-9996
Language: English
Published on: Apr 26, 2022
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2022 Francesco Di Gennaro, Rossana Lattanzio, Giacomo Guido, Aurelia Ricciardi, Roberta Novara, Giulia Patti, Sergio Cotugno, Elda De Vita, Gaetano Brindicci, Michele Fabiano Mariani, Luigi Ronga, Carmen Rita Santoro, Federica Romanelli, Stefania Stolfa, Roberta Papagni, Davide Fiore Bavaro, Giusi De Iaco, Annalisa Saracino, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.